Pluristem Therapeutics, Inc. (PSTI) Set to Announce Quarterly Earnings on Monday

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, September 11th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) opened at 1.19 on Monday. The firm has a 50-day moving average price of $1.17 and a 200 day moving average price of $1.27. The firm’s market cap is $114.63 million. Pluristem Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $1.85.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://sportsperspectives.com/2017/09/04/pluristem-therapeutics-inc-psti-set-to-announce-quarterly-earnings-on-monday.html.

Several analysts have recently commented on the company. Maxim Group set a $2.00 price objective on Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 16th. ValuEngine lowered Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday. Finally, HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a report on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Pluristem Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.31.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply